Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.